A study conducted by the Murdoch Children’s Research Institute has found little evidence on the effectiveness of the common antidepressant fluoxetine (Prozac) in reducing obsessive-compulsive behaviors in children with autism spectrum disorders (ASD). Despite inconclusive evidence, over half of children with ASD are prescribed medication, with one-third receiving antidepressants.
The randomized clinical trial involved 146 participants aged 7.5 to 18 years, who were assigned to receive either fluoxetine or a placebo. While initial results showed behavioral improvements, additional analysis revealed no significant difference between the fluoxetine and placebo groups. This study highlights the need for more evidence-based decision-making regarding the prescription of psychoactive medications for children with ASD.
The original article can be found here.
You can read about similar articles here.
